Symptoms include loud snoring, gasping during sleep, apnoeas, unrefreshing sleep, and excessive daytime sleepiness.
Obesity, retro- or micrognathia, oropharyngeal narrowing, and macroglossia are common physical features.
Diagnosis is established using clinical evaluation plus polysomnography or portable sleep tests.
Positive airway pressure or oral appliances are non-invasive treatment options.
In patients unable to adhere to medical therapy or with discrete anatomical sites of obstruction, soft tissue and/or skeletal surgery may be selected for treatment of obstructive sleep apnoea.
Complications of untreated obstructive sleep apnoea include increased risk of premature death, MI, dysrhythmias, stroke, HTN, motor vehicle accidents, metabolic syndrome, and neurocognitive dysfunction.
Complications of continuous positive airway pressure (CPAP) treatment include sleep disturbance, rhinitis, dermatitis, conjunctivitis, aerophagia, and dyspnoea. Complications of oral appliance therapy include occlusal changes and facial pain. Complications of surgery include bleeding, haematoma, velopharyngeal insufficiency, pharyngeal stenosis, dysphagia, airway obstruction, and, very rarely, death.
Obstructive sleep apnoea (OSA) is characterised by episodes of complete or partial upper airway obstruction during sleep. Episodic airway obstruction is usually associated with oxyhaemoglobin desaturations and arousals from sleep. The symptoms of sleep apnoea include chronic snoring, insomnia, gasping and breath holding, unrefreshing sleep, and daytime sleepiness.
The diagnosis of OSA may be confirmed if the Apnoea-Hypopnoea Index (the sum per hour of episodes of apnoeas and hypopnoeas) or Respiratory Distress Index (the sum per hour of episodes of apnoea, hypopnoea, and respiratory effort-related arousals) established with polysomnography or portable sleep test is ≥15 episodes/hour. However, 5 episodes/hour is considered sufficient for diagnosis if additional symptoms or comorbidities are present.
Assistant Clinical Professor
Department of Otolaryngology
Icahn School of Medicine at Mount Sinai
OJ is an unpaid advisor for ImThera medical and has received research funding support from ImThera Medical for the THN2 and THN3 FDA clinical trials. This topic discusses implantable hypoglossal neurostimulation devices and ImThera Medical is 1 of 3 companies in this field. Discussion is limited to available scientific evidence and there is no contractual agreement to disseminate product information. OJ is a consultant for Nyxoah Medical, which is developing a new implantable hypoglossal neurostimulation device. This device is not mentioned in the topic, as no published studies exist at the time of publication. The general topic is included in the topic. There is no contractual agreement to disseminate product information.
Professor of Medicine
Bahiana School of Medicine and Public Health
CD has been reimbursed by Sanofi-Aventis, Novartis, Merck Sharp Dohme, and Eli Lilly as investigator of clinical trials.
Adjunct Assistant Professor
University of Utah
Pulmonary & Critical Care Research
IHC Urban South Intermountain Utah Valley Pulmonary Clinic
KMS declares that he has no competing interests.
Use of this content is subject to our disclaimer